# Jacek Jassem

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jacek-jassem/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,564 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 87 |
| i10-index | 348 |
| Last Known Institution | Gdańsk Medical University |
| OpenAlex ID | https://openalex.org/A5004874011 |
| ORCID iD | https://orcid.org/0000-0002-8875-6747 |
| Works | 1,007 |

## Researcher papers

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-exemestane-after-two-to-three-years-of-tamoxifen-therapy/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial](https://scholariq.org/papers/survival-and-safety-of-exemestane-versus-tamoxifen-after-2-3-years-tamoxifen/)
- [Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer](https://scholariq.org/papers/final-results-from-prime-randomized-phase-iii-study-of-panitumumab-with-folfox4/)
- [A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo](https://scholariq.org/papers/a-dll3-targeted-antibody-drug-conjugate-eradicates-high-grade-pulmonary/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-of-the-mage-a3-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Gdańsk Medical University](https://scholariq.org/institutions/gdansk-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.